Jansen, Fenna M. http://orcid.org/0000-0001-5454-4335
Smits, Lisa J. T.
Thomas, Pepijn W. A.
de Jong, Dirk J.
Kreijne, Joany E.
van Dop, Willemijn A.
den Broeder, Nathan
Hoentjen, Frank
Article History
Received: 16 September 2022
Accepted: 6 April 2023
First Online: 2 May 2023
Declarations
:
: D.J. de Jong received consulting fees from Synthon, Pharma, Abbvie, and MSD, and travel fees from Falk Pharma, Takeda, Abbvie, MSD, Ferring, Vifor Pharma, and Cablon Medical. F. Hoentjen has served on advisory boards, or as speaker or consultant for Abbvie, Celgene, Janssen-Cilag, MSD, Takeda, Teva, Sandoz, and Dr. Falk, and has received unrestricted grants from Dr. Falk, Janssen-Cilag, Abbvie, Takeda. Other authors have no potential conflict of interest to disclose.
: This study was approved by the Radboud University Medical Center Committee on Research Involving Human Subjects (2017-3656).
: All participants provided written consent.